Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

eFFECTOR, Merck, and Pfizer commence combo trial for microsatellite stable CRC

Executive Summary

Pfizer Inc., Merck KGAA, and eFFECTOR Therapeutics Inc. entered into a trial collaboration agreement to study a combination of Merck and Pfizer’s avelumab with eFFECTOR’s eFT508 as a potential treatment for microsatellite stable colorectal cancer.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Immuno-Oncology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Trial Collaborations
    • R&D (No Licensing)

Related Companies